## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.4% below STRENGTH zone (3.0-6.0%); PEG 1.09 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($111.58)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 3, Bearish: 1)

**1. Schroder Investment Management Group Sells 39,629 Shares of DaVita Inc. $DVA**
- Source: MarketBeat | 20251204T120941 | Somewhat-Bearish | Relevance: 100%
- Schroder Investment Management Group reduced its stake in DaVita Inc. by 36% in the second quarter, selling 39,629 shares and now owning 70,431 shares worth approximately $10.03 million. Despite this, other institutions like Neuberger Berman and Norges Bank increased their holdings, leading to institutional ownership of about 90.12%. Analysts have a "Reduce" consensus rating with an average target price of $148.00, following DaVita's missed quarterly EPS and conservative FY2025 guidance.

**2. DaVita - More Volatile But Better Upside Than Fresenius (NYSE:DVA)**
- Source: Seeking Alpha | 20251203T093000 | Bullish | Relevance: 100%
- DaVita (DVA) is rated a speculative 'Buy' due to undervaluation and its dominant US dialysis network, despite earnings volatility and reliance on Medicare reimbursement. Trading below 11.5x P/E, DVA offers potential double-digit annual returns if it regains historical valuation multiples. Key risks include Medicare rate cuts, earnings misses, and high leverage, necessitating careful position sizing for risk-tolerant investors.

**3. Quantbot Technologies LP Acquires 50,040 Shares of DaVita Inc. $DVA**
- Source: MarketBeat | 20251204T131011 | Somewhat-Bearish | Relevance: 100%
- Quantbot Technologies LP significantly increased its stake in DaVita Inc. (NYSE:DVA) by 1,071.3% in the second quarter, acquiring an additional 50,040 shares, bringing its total to 54,711 shares valued at $7.79 million. This increase comes despite a weakening analyst sentiment, with many firms downgrading the stock and setting a consensus price target of $148.00 against the current trading price of around $119. DaVita missed Q3 EPS expectations but provided FY2025 guidance that analysts anticipate to be met.

**4. Edgestream Partners L.P. Invests $6.38 Million in DaVita Inc. $DVA**
- Source: MarketBeat | 20251204T032541 | Bearish | Relevance: 100%
- Edgestream Partners L.P. has acquired a new stake of 44,754 shares in DaVita Inc. (NYSE:DVA), valued at approximately $6.38 million, representing 0.06% ownership. This comes as DaVita recently missed quarterly earnings expectations and received multiple price target cuts, leading to a consensus "Reduce" rating from analysts. The stock is currently trading near $119, with a market capitalization of $8.41 billion.

**5. Catalyzing Change in Specialty Care: DaVita Shares Vision for Technology Transformation**
- Source: ACCESS Newswire | 20251202T103500 | Bullish | Relevance: 100%
- DaVita shared its vision for technology transformation in specialty care, emphasizing how technology can help address healthcare fragmentation for the 129 million Americans living with chronic conditions. Joel Haugen, Chief Product Officer for DaVita, highlighted the significant medical spend in specialty care and the potential of solutions like the DaVita Care Connect mobile app to enhance patient engagement through user-friendly interfaces. The article stresses the need for intentional change, prioritizing the experience of both patients and care teams, and fostering collaboration among stakeholders to scale solutions and reduce care fragmentation.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($54.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $55M sold (3 transactions in 90 days).
2. High short interest (21.1%, 7.3 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 14.3% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.09 suggests fair value with growth premium. Forward P/E 9.2x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($55.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.1B |
| Beta | 0.99 |
| 52W Range | $113.12 - $179.60 |
| Short Interest | 21.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.09 |
| Forward P/E | 9.2 |
| Current P/E | 11.0 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.9% to -3.4% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.4pp (needs >3.0% for momentum thesis). Below SMA200 (0.86x), long-term trend not supportive. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.41% (CS: 16) | Weak |
| RSI_14 | 39.8 | Neutral |
| MACD Histogram | 0.19 | Bullish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 0.945x | Below |
| vs SMA200 | 0.857x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $117.28
- **Stop Loss:** $111.58 (4.9% risk)
- **Target:** $122.98 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 87
- **Position Value:** $10,203.36
- **Portfolio %:** 10.20%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*